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IL-21-mediated reversal of NK cell exhaustion
facilitates anti-tumour immunity in MHC class
I-deﬁcient tumours
Hyungseok Seo1, Insu Jeon1, Byung-Seok Kim2, Myunghwan Park1, Eun-Ah Bae1, Boyeong Song1,
Choong-Hyun Koh3, Kwang-Soo Shin3, Il-Kyu Kim1,3, Kiyoung Choi4, Taegwon Oh4, Jiyoun Min5,
Byung Soh Min6, Yoon Dae Han6, Suk-Jo Kang5, Sang Joon Shin7, Yeonseok Chung2 & Chang-Yuil Kang1,3,4
During cancer immunoediting, loss of major histocompatibility complex class I (MHC-I) in
neoplasm contributes to the evasion of tumours from host immune system. Recent studies
have demonstrated that most natural killer (NK) cells that are found in advanced cancers are
defective, releasing the malignant MHC-I-deﬁcient tumours from NK-cell-dependent immune
control. Here, we show that a natural killer T (NKT)-cell-ligand-loaded tumour-antigen
expressing antigen-presenting cell (APC)-based vaccine effectively eradicates these
advanced tumours. During this process, we ﬁnd that the co-expression of Tim-3 and PD-1
marks functionally exhausted NK cells in advanced tumours and that MHC-I downregulation
in tumours is closely associated with the induction of NK-cell exhaustion in both tumour-
bearing mice and cancer patients. Furthermore, the recovery of NK-cell function by IL-21 is
critical for the anti-tumour effects of the vaccine against advanced tumours. These results
reveal the process involved in the induction of NK-cell dysfunction in advanced cancers and
provide a guidance for the development of strategies for cancer immunotherapy.
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A
lthough a number of anti-cancer immunotherapies
are currently being investigated in clinical trials, one
of the major obstacles in treating advanced cancer is
that tumour cells escape host immune responses via the
downregulation of major histocompatibility complex class I
(MHC-I)1,2. The malignant transformation and subsequent
selection of highly metastatic cells by the immune system
result in the loss of MHC class I in the neoplasm, contributing
to tumour evasion from immunosurveillance by cytotoxic
T lymphocytes. In addition, the downregulation of MHC class I
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Figure 1 | MHC class I downregulation affects anti-tumour immunity. (a) Each group of mice (n¼ 6) was vaccinated with the indicated cellular vaccine at
day 6 after TC-1 tumour s.c. injection (1 105) at day 0. (b) Each group of mice (n¼ 8) was vaccinated with the indicated cellular vaccine at day 10, 24 and
41 after TC-1 tumour s.c. injection (5 105) at day 0. The tumour size was measured three times weekly. (c,d) Each group of mice (n¼ 10) was vaccinated
with the indicated cellular vaccine at day 7, 14 and 21 after TC-1 tumour i.v. injection (1 105) at day 0. (d) In vivo imaging of TC-1 metastatic mice (day 40)
treated with metalloproteinase. (e) Expression of H-2Kb and H-2Db on tumours. C57BL/6 mice were implanted in the ﬂank with 1 105 TC-1 cells (day 0
indicates in vitro cultured tumour cells). (f) H-2Kb and H-2Db expression (e) is shown with tumour size. (g,h) Each graph depicts the speciﬁc lysis of
extracted TC-1 cells at different time points. CD8þ Tcells and NK cells were isolated from the spleens of B/Mo/E6E7/aGC-immunized mice at days 1 and
7 as effector cells. (i) The data presented in g–h reassembled with the H-2Kb and H-2Db level on tumours and the percentage of speciﬁc lysis when the
effector-to-target ratio was 30:1. The data in a were analysed by two-way analysis of variance (ANOVA) with Bonferroni multiple comparison tests. The
data in c were analysed using a log-rank (Mantel–Cox) test (conservative) *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. The data are representative
of three independent experiments that included three to ten mice per group. All values represent the mean±s.e.m.
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in tumours induces natural killer (NK)-cell dysfunction, leading
to the outgrowth of MHC class I-deﬁcient tumours3,4. However,
the underlying mechanisms involved in the induction of NK-cell
dysfunction by MHC class I-deﬁcient tumour cells and the best
way to overcome the tolerogenic tumour microenvironment in
advanced cancer remain to be elucidated5.
Co-inhibitory receptors, such as programmed death 1 (PD-1)
and T-cell immunoglobulin and mucin domain 3 (Tim-3), play a
crucial role in mediating T-cell exhaustion in both viral infections
and tumours6,7. The expression of these receptors has been
identiﬁed in diverse immune cell populations including T cells, B
cells and myeloid cells. Although previous studies demonstrated
that the PD-1/PD-L1 and Tim-3/ligands of Tim-3 signalling
down-modulated the cytotoxicity of NK cells against tumour
cells8,9, their expression on NK cells was not well documented
until a few recent human studies reported PD-1 and Tim-3
expression on NK cells of cancer patients10,11. Nevertheless, the
roles of these inhibitory receptors in the anti-cancer effector
functions of NK cells remain elusive.
The IL-21 receptor (IL-21R) is expressed on NK, B, T and
dendritic cells12. Several studies have reported that IL-21 acts
directly on viral antigen-speciﬁc CD8þ T cells to enhance their
functional responses and to limit exhaustion during chronic viral
infection13–15. IL-21 promotes the maturation of NK cell
progenitors and activates the anti-tumour effects of NK cells
through the NKG2D pathway16,17. In addition, IL-21 activates
cytotoxic programs in both CD8þ T and NK cells, thus providing
potent cytotoxic effector arms against cancer cells18. Based on
these studies, several clinical trials are currently underway19.
We have previously reported that an invariant natural killer T
(NKT) cell ligand, alpha-galactosylceramide (aGC), loaded on a
tumour antigen (tAg)-expressing B cell- and monocyte-based
vaccine (B/Mo/tAg/aGC) elicited diverse anti-tumour immune
responses20–22. In this study, we found that B/Mo/tAg/aGC
effectively eradicated otherwise resistant MHC class I-deﬁcient
tumour cells by activating NKT cells and inducing tumour
antigen-speciﬁc cytotoxic T-cell responses. Whereas MHC class
I-deﬁcient tumour cells selectively induced Tim-3þPD-1þ NK
cells with impaired cytotoxicity in the tumour microenvironment,
B/Mo/tAg/aGC vaccination restored the cytotoxic capacity of NK
cells. In addition, we found that the functional recovery of
exhausted Tim-3þPD-1þ NK cells by vaccination was solely
dependent on the activation of PI3K-AKT-Foxo1 and STAT1
signalling pathways by IL-21 produced by NKT cells.
Accordingly, the addition of recombinant IL-21 restored the
function of intratumoural Tim-3þPD-1þ NK cells both in
animal models and in human cancer patients.
Results
Effects of the vaccine for advanced tumours. To investigate
whether B/Mo/tAg/aGC has anti-tumour effects on large estab-
lished tumours, we ﬁrst developed a B/Mo/tAg/aGC vaccine
expressing the E6/E7 tumour Ag of human papillomavirus-
associated cancer (B/Mo/E6E7/aGC). We found that B/Mo/E6E7/
aGC elicited activation of NKT (Supplementary Fig. 1A) and NK
cells (Supplementary Fig. 1B) and induced antigen-speciﬁc CTL
responses (Supplementary Fig. 1C). A single vaccination on day 7
with B/Mo/E6E7/aGC was successful for the treatment of mice
bearing small E6/E7-expressing TC-1 tumours (Fig. 1a) and
protected mice against tumour re-growth (Supplementary Fig. 2).
Multiple vaccinations at late time points effectively eradicated
large established TC-1 tumours (Fig. 1b), and lung metastases
derived from TC-1 tumour cells were efﬁciently eradicated by
vaccination with B/Mo/E6E7/aGC (Fig. 1c,d). To investigate the
effects of B/Mo/E6E7/aGC on MHC class I-downregulated
tumours, we analysed the kinetics of H-2Kb and H-2Db expres-
sion on tumours. A gradual downregulation of H-2Kb and H-2Db
was observed with tumour progression (Fig. 1e,f). The cytotoxic
activity of NK cells gradually increased during tumour progres-
sion, while the cytotoxicity of CD8þ T cells gradually decreased
(Fig. 1g,h). The cytotoxicity of NK cells was inversely correlated
with the expression of H-2Kb and H-2Db on tumours, whereas
that of CD8þ T cells was positively correlated with the expres-
sion of H-2Kb and H-2Db (Fig. 1i). This observation prompted us
to address whether MHC class I-deﬁciency can affect NK cell
functions23. To this end, we established H-2Kb and H-2Db KO or
b2-microglobulin (b2m)-deﬁcient tumours (Supplementary
Fig. 3A,B). The progression of tumour growth in the respective
syngeneic mice was comparable between WT and MHC class
I-deﬁcient tumours (Supplementary Fig. 3C–E).
Several mouse and human studies have shown that NKT-cell
activation triggers anti-tumour immune responses by enhancing
NK cell activation24,25. To verify that this was also the case with
MHC class I-deﬁcient tumours, mice were injected with aGC-
loaded B cells and monocytes (B/Mo/aGC) followed by MHC
class I-deﬁcient tumour inoculation. The B/Mo/aGC
administration resulted in a reduction in the growth of MHC
class I-deﬁcient tumours compared with B/Mo (Fig. 2a–c). We
also found that treatment with anti-NK1.1 or anti-asialo GM1
signiﬁcantly reversed the inhibition of tumour growth, which
indicated that the anti-tumour immunity was dependent on NK
and NKT cells (Supplementary Fig. 4 and Fig. 2d–f). However,
human malignant primary tumours are well known for their
heterogeneous MHC class I expression levels2,26. Therefore, we
hypothesized that NKT-cell-ligand-loaded tumour antigen-
expressing vaccination can eradicate both MHC class
I-sufﬁcient and MHC class I-deﬁcient tumour cells by inducing
adaptive and innate immune responses. MHC class I-sufﬁcient
tumours could be eradicated by adaptive immune responses, such
as CD8þ T cells, and MHC class I-deﬁcient tumours could be
eradicated by innate immune responses, such as the response of
NK cells. To address this hypothesis, we established a
heterogeneous tumour model in which a mixture of MHC class
I sufﬁcient- and MHC class I-deﬁcient tumour cells was
inoculated at different ratios. The data revealed that our vaccine
regimen induced complete tumour eradication and a long-lasting
cure in 90% of the mice bearing heterogeneous tumours and thus
contain up to 10% MHC class I-deﬁcient TC-1 tumour cells
(Fig. 2g,h). B/Mo/E6E7/aGC administration induced robust
tumour eradication and durable cures in 470% of the mice
bearing heterogeneous tumours, which contained 20% MHC class
I-deﬁcient TC-1 tumour cells. In contrast, B/Mo/E6E7 or B/Mo/
aGC administration elicited weaker anti-tumour responses and
reduced survival rates (Fig. 2i). Antibody depletion experiments
showed that CD8þ T and NK cells were crucial for heterogenic
tumour eradication and led to reductions in the survival rates
(Fig. 2j). These results indicate that our vaccine regimen is
effective against the heterogeneous tumours by inducing both
adaptive and innate immune responses.
MHC-I-deﬁcient tumours induce Tim-3 and PD-1 on NK cells.
Although recent studies have demonstrated that MHC class
I-downregulation or deﬁciency in tumour cells induces NK cell
anergy, NKT-cell-ligand-loaded antigen-presenting cell (APC)-
based tumour Ag-expressing vaccination efﬁciently induced the
eradication of tumours containing MHC class I-deﬁcient cells.
From this perspective, we hypothesized that NK anergy in mice
bearing MHC class I-deﬁcient tumours might have been restored
by the vaccination. To investigate this possibility, we analysed the
cell surface marker expression pattern and cytotoxic function of
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NK cells in MHC class I-deﬁcient tumour microenvironments.
Recent studies have suggested that Tim-3 expression is a marker
of NK-cell activation or exhaustion9,10. We observed that Tim-3
expression on tumour-inﬁltrating NK cells was dramatically
accelerated in mice bearing H-2Kb and H-2Db KO tumours
compared with WT tumour-bearing mice, and most Tim-3þ NK
cells co-expressed PD-1 (Fig. 3a). The levels of Tim-3 and PD-1
expression on NK cells in the spleen were very low, regardless of
the MHC class I expression on tumours, but those in tumour-
draining lymph nodes (TdLNs) were slightly increased in
mice bearing H-2Kb and H-2Db KO tumours compared with
WT tumour-bearing mice, although this increase was not
statistically signiﬁcant (Supplementary Fig. 5). The expression
levels of NK-cell-activating receptors, including Ly49D, DNAM-
1, CD69 and CD160, were signiﬁcantly higher in Tim-3þ PD-1þ
NK cells compared with Tim-3PD-1 cells. The expression of
NK-ell-inhibitory receptors such as NKG2A/C/E, KLRG1, TIGIT
and 2B4 was comparable between the groups, but Ly49A was
downregulated in Tim-3þPD-1þ NK cells (Fig. 3b). To
investigate whether the tumours could directly induce the
expression of Tim-3 and PD-1 on NK cells, we co-cultured
puriﬁed NK cells with tumour cells. When NK cells were co-
cultured with WT tumour cells, Tim-3 was slightly induced
starting on day 1, and PD-1 was not induced until day 5.
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Figure 2 | Eradication of heterogeneous tumours by induced adaptive and innate immune responses. (a–c) Subcutaneous growth of WTand MHC class
I knockout (KO) tumour cells (TC-1, MC38: H-2Kb and H-2Db KO, CT26: b2m KO) in each group of mice (n¼6) treated with B/Mo (1 106), B/Mo/aGC
(1 106) and aGC (1mg) every 7 days. (d–f) Subcutaneous growth of the indicated tumour cells in each group of mice (n¼ 6) treated with B/Mo (1 106)
or B/Mo/aGC (1 106) every week. The tumour-bearing mice were treated with control IgG, anti-NK1.1 (PK136) or anti-asialo GM-1 to deplete NK cells on
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before initiation of the vaccination. Each group of mice (n¼ 12) was vaccinated with the indicated cellular vaccine every 7 days after s.c. injection of the
mixed (TC-1 WT and MHC class I-deﬁcient tumour ratio¼ 80:20) tumours (1 105) at day 0. a–g were analysed by a two-way ANOVA with Bonferroni
multiple comparison tests. The data in h–j were analysed by a log-rank (Mantel–Cox) test (conservative) *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
The data are representative of three independent experiments that included six to ten mice per group. All values represent the mean±s.e.m.
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However, when NK cells were co-cultured with MHC class
I-deﬁcient tumour cells, Tim-3 was highly induced starting on
day 1, and PD-1 was induced on day 5 (Supplementary Fig. 6A).
To analyse whether soluble factors produced by tumours could
induce Tim-3 and PD-1, NK cells were both co-cultured with
MHC class I-deﬁcient tumour cells using a transwell system and
in tumour-conditioned medium. The expression of Tim-3 and
PD-1 on NK cells was induced when the NK cells and MHC class
I-deﬁcient tumours were directly co-cultured (Supplementary
Fig. 6B). In human NK cells, Tim-3 expression was rapidly
upregulated upon co-culture with b2m-deﬁcient HeLa cells
compared with NK cells co-cultured with WT HeLa cells
(Fig. 3c). Human NK-cell-activating receptors, including
NKG2D, DNAM-1 and CD69, and the inhibitory receptor 2B4
were signiﬁcantly upregulated on Tim-3þ NK cells compared to
Tim-3 cells. However, expression of the inhibitory receptor
KLRG1 was signiﬁcantly downregulated in Tim-3þ NK cells
(Fig. 3d). The levels of PD-1 on Tim-3þ NK cells were slightly
higher than those on Tim-3 cells (Fig. 3e). These results
collectively suggest that Tim-3þPD-1þ NK cells express higher
levels of activating receptors.
Tim-3þ PD-1þ NK cells are functionally exhausted in tumour.
Although Tim-3 and PD-1 were initially suggested to be activa-
tion markers of T cells, recent studies have demonstrated that
Tim-3 and PD-1 co-expression is a marker of exhausted T cells
after repeated TCR stimulation during chronic infection or in the
60
WT
Day 8
a b
dc
e
Day 12
Day 16
Day 20
Day 3
Day 2
Day 1
Day 0
Isotype
Day 3
Day 2
Day 1
Day 0
Isotype
3.07
104
104
103
103
0
0
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
105
104
–103
101 102 103 104 105
100
80
60
40
20
0
–103103 103104 104105 1050 0
103
0
105
104
103
0
105
104
103
0
105
105
1041030 105
1041030 105 1041030 105
1041030 105
1041030 105
1041030 1051041030 105
7.94
1.80 10.1 6.86 37.3
4.28
39.014.813.53.61
4.39
45.3
9.76
17.317.3
4.73
Tim-3
Tim-3
PD-1
PD
-1
%
 o
f m
ax
%
 o
f m
ax
6.83
5.93
0.82
23.2
0.78 5.91 1.97
KO
100
80
60
40
20
0
Ly
49
D
DN
AM
-1
DN
AM
-1
NK
G2
D
CD
69
CD
69
CD
16
0
CD
16
0
NK
G2
A/C
/E
Ly
49
A
KL
RG
1
KL
RG
1
TIG
IT
TIG
IT
2B
4
2B
4
%
 o
f T
im
-3
+
 N
K 
ce
ll
%
 o
f N
K 
ce
ll
%
 o
f N
K 
ce
ll
%
 o
f T
im
-3
+
 P
D
-1
+
 N
K 
ce
ll
%
 o
f T
im
-3
+
 N
K 
ce
lls
CD16+ CD56dim Tim-3– CD16+ CD56dim NK cell
CD16+ CD56dim NK cell
Tim-3+ CD16+ CD56dim NK cellWith HeLa WT With HeLa β2m KO
HeLa WT
HeLa β2m KO100
150
100
50
0
80
60
40
20
0
0 1 2 3
Tim-3–, PD-1–
Tim-3–
200
150
PD
-1
 M
.F
.I.
100
50
0
Tim-3+
Tim
-3
–
Tim
-3
+
Tim-3+, PD-1+
***
**
**
**
*
*
***
***
***
****
***
*
*
n.s
***
**
**
**
**
40
20
0
50
40
30
20
10
0
4 8 12 16 20 24
4 8 12 16 20
WT
KO
24
Days after tumour challenge
Days after tumour challenge
Days after co-culture
Figure 3 | Natural killer cells in MHC class I-deﬁcient tumours exhibit accelerated Tim-3 and PD-1 expression. (a) The kinetic expression levels of Tim-3
and PD-1 on tumour-inﬁltrating natural killer cells from TC-1 WT or H-2Kb and H-2Db KO tumour-bearing mice (n¼ 5) were analysed by ﬂow cytometry.
(b) Tim-3þPD-1þ or Tim-3PD-1 NK cells from TC-1 H-2Kb and H-2Db KO tumours were stained with antibodies for the activating receptors Ly49D,
DNAM-1, CD69 and CD160 or the inhibitory receptors NKG2A/C/E, Ly49A, KLRG1, TIGITand 2b4. (c) The Tim-3 expression level on human NK cells was
analysed after CD16þCD56dim human NK cells (n¼6) were co-cultured with HeLa WTor b2m KO cells. (d) Tim-3þ or Tim-3 human NK cells (n¼ 8)
co-cultured with HeLa b2m KO cells for 3 days were stained with antibodies for the activating receptors NKG2D, DNAM-1, CD69 and CD160 or the
inhibitory receptors TIGIT, KLRG1,2B4 and PD-1 (e). The data in a,c,d,e were analysed by a two-tailed unpaired Student’s t-test. *Po0.05, **Po0.01,
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cancer microenvironment7,27. To investigate whether Tim-3þ
PD-1þ NK cells induced by MHC class I-deﬁcient tumours
represent activated or exhausted NK cells, we analysed the
effector functions of NK-cell populations isolated from mice
bearing WT or H-2Kb and H-2Db KO tumours. We determined
that the frequency of IFN-gþ NK cells was remarkably decreased
in tumour-inﬁltrating lymphocytes (TILs) and TdLNs of mice
bearing H-2Kb and H-2Db KO tumours compared with those
bearing WT tumours (Supplementary Fig. 7C), although the
frequency and number of NK cells were comparable between the
two groups (Supplementary Fig. 7A,B). ERK1/2 kinase is a crucial
factor for the induction of cytokine production and cytotoxicity
in NK cells28. The levels of phospho-ERK1/2 were signiﬁcantly
reduced in TIL NK cells from MHC class I-deﬁcient tumour-
bearing mice compared with TIL NK cells from WT tumour-
bearing mice (Supplementary Fig. 8A).
To investigate the interrelationship between Tim-3 and PD-1
expression and function on NK cells, we analysed the kinetics of
the expression of these receptors and the IFN-g secretion of
intratumoural NK cells from mice bearing WT and H-2Kb and H-
2Db KO tumours. In mice bearing WT tumours, the expression of
Tim-3 and PD-1 on intratumoural NK cells reached 50% at 28
days after tumour injection. In contrast, Tim-3 and PD-1 were
expressed much more rapidly on intratumoural NK cells from
mice bearing H-2Kb and H-2Db KO tumours than on intratu-
moural NK cells from mice bearing WT tumours, reaching up to
70% at 28 days after tumour injection. We also observed that IFN-
g production of intratumoural NK cells from both groups of mice
sharply decreased in response to the increased expression of Tim-3
and PD-1 (Fig. 4a). Of note, among the NK cells isolated from
MHC class I-deﬁcient tumours, Tim-3þ PD-1þ NK cells
exhibited a dramatically reduced expression of effector molecules
such as IFN-g, CD107a, granzyme B and perforin compared with
their Tim-3PD-1 counterparts (Fig. 4b). These results suggest
that when NK cells are stimulated, Tim-3 and PD-1 are ﬁrst
expressed on NK cells as an activation signature. However, after
persistent stimulation in the absence of MHC class I, Tim-3þ
PD-1þ expression represented the exhausted NK-cell population.
In addition, T-bet expression on Tim-3þPD-1þ NK cells in
H-2Kb and H-2Db KO tumours was also reduced compared with
Tim-3PD-1 NK cells, whereas the expression of Eomes was
somewhat increased on Tim-3þPD-1þ NK cells (Fig. 4c).
Moreover, ERK1/2 phosphorylation was signiﬁcantly decreased
in Tim-3þPD-1þ NK cells (Fig. 4d). Consistent with their
exhausted phenotype, the cytotoxicity of the Tim-3þPD-1þ NK
cells against H-2Kb and H-2Db KO TC-1 tumours was much lower
than the cytotoxicity exhibited by Tim-3 PD-1 NK cells
(Fig. 4e). We also found that Tim-3þPD-1þ intratumoural NK
cells in WT tumour-bearing mice had a similar exhausted
phenotype, in accordance with the spontaneous downregulation
of MHC class I on WT tumour cells (Supplementary Fig. 8B).
To determine whether the PD-1/PD-L1 axis transmits negative
signals on NK cells, we examined whether the tumour cells
expressed PD-L1. Our data showed that MC38 tumour cells had a
high expression level of the PD-L1 molecule on their surface
(Supplementary Fig. 9A). To examine the effect of anti-PD-1
antibody on exhausted NK cells, we treated MC38 H-2Kb and
H-2Db KO tumour-bearing mice, which were depleted of CD8þ
T cells by 2.43 mAb, with the anti-PD-1 antibody. This treatment
signiﬁcantly suppressed tumour growth in mice bearing MC38
H-2Kb and H-2Db KO tumours (Supplementary Fig. 9B).
Collectively, our data suggest that the PD-1/PD-L1 axis transmits
negative signals on NK cells and that blocking the PD-1 signal
could restore the anti-tumour effects of exhausted NK cells.
When human NK cells were co-cultured with b2m-deﬁcient HeLa
cells, the IFN-g and granzyme B levels in Tim-3þ NK cells were
gradually decreased after restimulation with the NKG2D ligand
ULBP-2 (Supplementary Fig. 10A). A gradual reduction in T-bet
expression in Tim-3þNK cells was highly correlated with the
pattern of IFN-g production, whereas the expression pattern of
Eomes was opposite that of T-bet (Supplementary Fig. 10B).
Altogether, these data suggest that repeated stimulation of NK
cells by MHC class I-deﬁcient tumours induces the functional
exhaustion of NK cells marked by the co-expression of Tim-3 and
PD-1 in mice and humans.
IL-21 reverses the functions of exhausted NK cells. Given that
vaccination with B/Mo/aGC effectively controls the growth of
MHC class I-deﬁcient tumours in an NK- and NKT-cell-depen-
dent manner, we hypothesized that the vaccination could revive
the otherwise defective effector functions of NK cells in mice
bearing MHC class I-deﬁcient tumours (Fig. 2a–f). Thus, we
investigated whether B/Mo/aGC could reverse the exhausted
status of NK cells. The frequency of IFN-g-producing NK cells
was dramatically increased with B/Mo/aGC vaccination com-
pared with B/Mo alone, regardless of the MHC class I expression
level in the tumours (Supplementary Fig. 11A). The increase in
IFN-g-producing NK cells upon B/Mo/aGC vaccination was
dependent on NKT cells because Ja281-deﬁcient mice failed to
demonstrate a similar increase (Supplementary Fig. 11B). NKT
cells are known to secrete various cytokines, including IFN-g, IL-
4, TNF-a and IL-21 (refs 29,30). When B/Mo/aGC was injected,
we conﬁrmed that the NKT cells produced IFN-g, IL4, TNF-a
and IL-21 (Fig. 5a, Supplementary Fig. 12A). Therefore, we next
sought to determine whether NKT-cell-produced cytokines were
responsible for the B/Mo/aGC-mediated recovery of NK cell
functions in H-2Kb and H-2Db KO tumours. Because IL-21 and
IFN-g are well-known stimulators of NK cell functions19,31, we
ﬁrst tested whether these cytokines could revive the effector
functions of exhausted NK cells in tumours. The addition of
IFN-g partially retrieved the IFN-g-producing capacity of
exhausted NK cells, whereas the addition of IL-21 completely
restored the functions of NK cells isolated from H-2Kb and
H-2Db KO tumours to levels comparable to those of NK cells
isolated from WT tumours (Fig. 5b). We also found that ERK
activation in NK cells was signiﬁcantly increased by both IFN-g
and IL-21 in vitro (Fig. 5c). However, the addition of IL-4 or
TNF-a did not retrieve the IFN-g-producing capacity of
exhausted NK cells (Supplementary Fig. 12B).
To conﬁrm the IFN-g- and IL-21-dependent reversal of NK
cell functions in vivo, we administered an anti-IFN-g-neutralizing
Ab or anti-IL-21R-blocking Ab after B/Mo/aGC vaccination. The
B/Mo/aGC-mediated recovery of IFN-g production and CD107a
degranulation in Tim-3þPD-1þ NK cells was signiﬁcantly
diminished in mice treated with the anti-IL-21R blocking Ab,
while partial inhibition was observed in mice treated with the
anti-IFN-g Ab (Fig. 5d). Analysis of perforin and granzyme B
production also conﬁrmed that the functional reversal of Tim-
3þPD-1þ NK cells by B/Mo/aGC was primarily IL-21-
dependent (Supplementary Fig. 13). The recovery of T-bet
expression in Tim-3þPD-1þ NK cells following B/Mo/aGC
vaccination was also completely abrogated by IL-21R blockade
(Fig. 5e). To address whether alterations in effector cytokine
production and T-bet expression could lead to changes in the
cytotoxicity exhibited by each NK-cell subset, we tested the
cytotoxicity of puriﬁed Tim-3 PD-1 and Tim-3þPD-1þ NK
cells isolated after B/Mo/aGC vaccination. We found that B/Mo/
aGC vaccination restored the cytotoxic functions of Tim-3þPD-
1þ NK cells in MHC class I-deﬁcient tumours and that IL-21 was
required for this process because the IL-21R blockade signiﬁ-
cantly abrogated the recovery of NK cell cytotoxicity (Fig. 5f).
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Consistent with these results, the regression of H-2Kb and
H-2Db KO TC-1 tumour growth following B/Mo/aGC vaccina-
tion was partially abrogated by IFN-g neutralization, while IL-
21R blockade almost completely restored tumour progression to
the same extent observed in unvaccinated mice (Fig. 5g). This
pattern was reproducible in two different MHC class I-deﬁcient
tumour models (Fig. 5h,i).
Next, we sought to determine whether IL-21 could directly
induce the functional recovery of exhausted NK cells in MHC
class I-deﬁcient tumours. To achieve this goal, we employed
Rag1 / mice to eliminate the effects of IL-21 on T cells. When
we intratumourally injected recombinant IL-21 (rIL-21) into
MC38 H-2Kb and H-2Db KO tumour-bearing Rag1 / mice,
tumour growth was signiﬁcantly inhibited with an increase in
tumour-inﬁltrating NK cells (Supplementary Fig. 14A,B).
Although the levels of Tim-3 and PD-1 expression were
decreased, the expression of IFN-g and CD107a was increased
by intratumoural injection of rIL-21 (Supplementary Fig. 14C–E).
To establish and isolate fully exhausted NK cells, we used an IFN-
g-eYFP-reporter (GREAT) mouse system. We isolated Tim-
3þPD-1þ eYFP NK cells from MC38 H-2Kb and H-2Db KO
tumour-bearing GREAT mice and stimulated them with anti-
NK1.1 in the presence of rIL-21. We observed that IFN-g
secretion of rIL-21-treated Tim-3þPD-1þ eYFP NK cells was
signiﬁcantly increased compared with that of vehicle-treated
Tim-3þPD-1þ eYFP NK cells (Fig. 5j). To analyse the direct
anti-tumour effects of rIL-21-treated Tim-3þPD-1þ eYFP NK
cells, these cells were adoptively transferred into IL-2Rg /
Rag2 / mice (lacking B cells, T cells and NK cells) bearing
MC38 H-2Kb and H-2Db KO tumours. We observed a signiﬁcant
inhibition of tumour growth in mice that received rIL-21-treated
Tim-3þPD-1þ eYFP NK cells. The growth inhibition in the
mice that received these cells was slightly higher, although not
statistically signiﬁcant, than that in mice that received Tim-
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3PD-1 NK cells (Fig. 5k). Collectively, our results suggest that
IL-21 could restore the function of exhausted Tim-3þPD-1þ NK
cells and effectively inhibit tumour progression.
IL-21 mediated mechanism of reversal of exhausted NK cells.
To further explore the underlying signalling mechanisms of
IL-21-mediated functional reversal of exhausted Tim-3þPD-1þ
NK cells, we examined the ERK/MAPK, PI3K-AKT and STAT
pathways because IL-21 has been suggested to be transduced via
these signalling pathways19. We found that IL-21 induced ERK,
AKT, STAT1 and STAT3 phosphorylation (Figs 5c and 6a,c,e).
When exhausted Tim-3þPD-1þ NK cells were pretreated
with various signalling inhibitors, IFN-g secretion and T-bet
upregulation by IL-21 were reduced in a dose-dependent manner
by Fludarabine (STAT1 inhibitor) and LY294002 (PI3K inhibitor)
(Fig. 6b,f,g). However, PD98059 (ERK inhibitor) and S31-201
(STAT3 inhibitor) did not reduce IFN-g secretion (Fig. 6d). We
also analysed the Foxo1 and T-bet transcription factors. The
PI3K-AKT pathway is known to enhance proliferation32 and
upregulate T-bet via Foxo1 phosphorylation33. The Foxo1
transcription factor negatively regulates the effector functions of
NK cells by inhibiting T-bet expression34. We found that
intratumoural rIL-21 treatment elicited Foxo1 phosphorylation
and T-bet upregulation in NK cells (Supplementary Fig. 15A).
We also conﬁrmed that the addition of exogenous rIL-21
induced Foxo1 phosphorylation in exhausted human NK cells
(Supplementary Fig. 15B). Collectively, these results suggest that
STAT1 and the PI3K-AKT-Foxo1 axis are crucial regulators
of the IL-21-mediated reversal of exhausted Tim-3þPD-1þ
NK cells.
Reversal of exhausted NK cells in cancer patients by IL-21.
Recently, PD-1þ and Tim-3þ NK cells were identiﬁed in the
tumour tissues of cancer patients11,35,36. However, the
characteristics of these intratumoural NK cells in cancer
patients have not yet been fully investigated. To conﬁrm the
presence of Tim-3þPD-1þ NK cells in cancer patients, we
analysed tumour tissues isolated from patients with different
types of cancer. When we isolated NK cells from human tumour
tissues based on CD16 and CD56 co-expression, the expression
levels of Tim-3 and PD-1 on intratumoural NK cells were
much higher than those in normal tissues of the same patients
(Fig. 7a,c). MHC class I expression in EpCamþ tumour tissues
was lower than that in EpCamþ normal tissues (Fig. 7b),
suggesting that Tim-3 and PD-1 expression on intratumoural NK
cells was presumably induced by MHC class I downregulation in
the tumour tissues of cancer patients.
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Functional analysis revealed that the effector function of
intratumoural Tim-3þPD-1þ NK cells was defective as follows:
the secretion of IFN-g and granzyme B and the cytotoxicity of the
Tim-3þPD-1þ NK cells were signiﬁcantly reduced compared
with those of the Tim-3PD-1 counterparts. Intriguingly,
however, rIL-21 treatment restored IFN-g and granzyme B
secretion and the cytotoxicity of Tim-3þPD-1þ NK cells to
levels comparable to those of Tim-3PD-1 NK cells (Fig. 7d,e,
Supplementary Fig. 16). Taken together, these results suggest that
the functional exhaustion of Tim-3þPD-1þ NK cells in the
tumour tissues of cancer patients can be restored by exogenous
IL-21 treatment.
Discussion
To date, MHC class I downregulation or deﬁciency has been
reported in the tumour microenvironment of patients with
various advanced cancers2,23,26. The tolerogenic tumour
microenvironment induced by MHC class I insufﬁciency in
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Figure 7 | Expression level of Tim-3 and PD-1 on intratumoural NK cells in cancer patients and rescue of exhausted Tim-3þ PD-1þ NK cells by IL-21.
(a) The expression of EpCam and CD45 in the primary tumour tissues or normal tissues was analysed by ﬂow cytometry. Intratumoural NK cells were
isolated by gradient centrifugation, followed by depletion of lineage (EpCam, CD3, CD19, CD14)þ cells. (b) HLA-ABC expression on gated EpCamþ
tumour or normal tissues from cancer patients. (c) Tim-3 and PD-1 expression on gated CD16þCD56þ intratumoural NK cells from cancer patients.
(d) Isolated Tim-3þPD-1þ or Tim-3PD-1 NK cells were incubated overnight in the presence or absence of rIL-21 (20 ngml 1) and stimulated with
anti-hNKp46 for 5 h. The IFN-g and granzyme B expression on the indicated cells is depicted. (e) Isolated Tim-3þPD-1þ or Tim-3PD-1 NK cells were
incubated overnight in the presence or absence of rIL-21 (20 ngml 1) and were co-cultured with 51Cr-labelled K562 cells as target cells. The data were
analysed by a two-tailed unpaired Student’s t-test *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. The data are cumulative from ﬁve (normal tissue) or
seven (tumour tissue) independent experiments. All values represent the mean±s.e.m.
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tumour cells is one of the major impediments to effective cancer
immunotherapy due to the restriction of the cytotoxicity of
T lymphocytes and the induction of NK-cell dysfunction5. Thus,
it remains an unsolved question whether the concomitant
activation of both adaptive and innate immune responses by
immunotherapies is sufﬁcient to overcome the tolerogenic
tumour microenvironment found in advanced cancers
containing MHC class I-deﬁcient cells. Here, we demonstrate
that both the induction of adaptive immune responses and the
reversal of NK-cell exhaustion are critical for the treatment of
late-stage cancers.
Previous studies have demonstrated that the activation of NK
cells is regulated by the integration of signals derived from
activation and inhibitory receptors expressed on their surface37.
For example, triggering inhibitory receptors on NK cells by the
ligation of MHC class I expressed on target cells interferes
with cytotoxicity-promoting signals from activating receptors,
resulting in the inhibition of target cell lysis by NK cells38.
In contrast, the downregulation of MHC class I on target cells
releases NK cells from inhibitory signals to induce target cell
lysis39. Paradoxically, MHC class I deﬁciency in advanced human
cancers has been associated with NK-cell hyporesponsiveness,
which suggests that MHC class I-deﬁcient tumour cells have
evolved to escape immunosurveillance by NK cells through
previously unrecognized effects on NK cells4,5,11,23. In this regard,
our ﬁndings provide direct evidence to explain why NK cells
in cancer patients are unable to kill MHC class I-deﬁcient or
low-expressing tumour cells.
Tim-3 and PD-1 have recently emerged as speciﬁc markers for
T-cell exhaustion during chronic viral infection and cancer
progression7,27. Although the functional exhaustion of NK cells
has also been demonstrated in both tumour-bearing mice and
cancer patients, cell surface markers that can identify exhausted
NK cells in the cancer microenvironment remain unclear10,35.
Here, we found that the co-inhibitory receptors Tim-3 and PD-1
marked functionally defective cells among tumour-inﬁltrating NK
cells in mice and humans alike and that tumour cells, especially
MHC class I-deﬁcient tumour cells, directly induced Tim-3þ
PD-1þ NK cells. We hypothesized that perhaps, similar to T-cell
studies in which multiple rounds of TCR stimulation induce
PD-1 in chronic viral infection, chronic interaction with MHC
class I-deﬁcient tumours induces these markers on NK cells. In
addition, the degranulation, cytokine secretion and cytotoxicity
of Tim-3þPD-1þ NK cells were more defective than those of
Tim-3PD-1 NK cells. Our study also showed that the
expression levels of Tim-3 and PD-1 on intratumoural NK cells
from patients with different types of cancer were much higher
than those in normal tissues of the same patients. We also found
that the expression of Tim-3 and PD-1 on intratumoural NK
cells was inversely correlated with MHC class I expression in
the tissues of cancer patients. Although previous studies have
demonstrated that PD-1 and Tim-3 expression on NK cells from
cytomegalovirus-infected or cancer patients transmits negative
signals on NK cell cytotoxicity8,10,11,35, a few unknown features
remain to be elucidated regarding the induction of the functional
exhaustion of NK cells, including (i) whether the ligation of
PD-1/PD-L1 or Tim-3/galactin-9 on NK cells is required for the
induction of NK-cell exhaustion, (ii) the molecular mechanism by
which NK-cell exhaustion is induced by tumour cells and (iii) the
molecular mechanisms involved in the upregulation of PD-1 and
Tim-3 on NK cells. For example, it has been demonstrated that
Tim-3 or PD-1 ligation on T cells inhibits TCR stimulation-
dependent signalling pathways and promotes exhaustion of
CD8þ T cells through the induction of NFAT40. Therefore,
further studies are needed to identify the precise mechanism by
which PD-1 and Tim-3 signalling inﬂuence the dysfunction of
NK cells and to address which molecular machineries are
involved in the induction of NK cell exhaustion during cancer
progression.
Previous studies have demonstrated that the production of
IFN-g by NK cells increases in a STAT1-dependent manner41,42,
whereas the cytotoxicity of NK cells is abrogated through the
STAT3 pathway43, suggesting that STAT1 and STAT3 can
oppose each other in the regulation of NK cells. In addition, the
MAPK/ERK and PI3K/AKT pathways are important for
promoting cytokine secretion and proliferation by NK cells44,45.
Our results suggest that IL-21 treatment induces STAT1, STAT3,
ERK and AKT phosphorylation. However, the functional reversal
of exhausted NK cells appears to be mediated by STAT1 and the
PI3K-AKT-Foxo1 pathway. These two mechanisms may act
synergistically to promote the functional reversal of NK-cell
exhaustion.
Prior studies have demonstrated that neo-antigens or various
antigens targeted by cancer immunotherapeutic vaccines are
important for inducing anti-tumour effects46–48 and that
combination therapy (checkpoint blockade, cancer vaccines,
cytokines and antibodies) with the induction of adaptive and
innate immune responses could eradicate large established
tumours in experimental mice49. In agreement with these
ﬁndings, our data suggest that the spontaneous downregulation
of MHC class I on tumour cells contributes to tumour evasion
from immunosurveillance; to our knowledge, these advanced
tumours have not previously been curable by a single
immunotherapy relying on endogenous immune responses, but
IL-21 secretion by NKT-cell-activating vaccination or IL-21-
mediated NK-cell therapies effectively eradicate these tumours by
reversing NK-cell exhaustion. We suggest that not only inducing
antigen-speciﬁc T cell and innate immune responses but also
restoring NK-cell exhaustion via IL-21 signalling are crucial for
overcoming cancer immuno-evasion. It may be important for
eliminating heterogeneous tumours containing MHC class
I-deﬁcient cells, which induce NK-cell exhaustion. In addition,
the provision of exogenous IL-21 may expand antigen-speciﬁc
CD8þ T cells and limit CD8þ T-cell exhaustion13–15,50. In this
regard, future studies should explore whether our vaccine could
also restore the exhaustion of CD8þ T cells in tumour
microenvironments through IL-21 produced by the activated
NKT cells.
To our knowledge, this is the ﬁrst report to deﬁne Tim-3þPD-
1þ NK cells as exhausted cells induced by MHC class I-deﬁcient
tumours in mice and humans. In addition, our study explains
how MHC class I-deﬁcient tumours escape cancer immunosur-
veillance, despite their increased susceptibility to NK cell-
mediated cell cytotoxicity during the initial stage. Furthermore,
we clearly demonstrated that IL-21 can reverse the functional
exhaustion of NK cells by activating both the PI3K-AKT-Foxo1
and STAT1 signalling pathways. Therefore, these ﬁndings
demonstrate that NK-cell exhaustion is an attractive drug target
for developing anticancer immunotherapies and show that
enhancing the concentration of IL-21 in the tumour microenvir-
onment can be highly beneﬁcial for the treatment of advanced
tumours enriched with dysfunctional NK cells.
Methods
Mice. Female C57BL/6 and BALB/c mice were purchased from Charles River
Laboratories (Seoul, Korea). The Ja281 / mice were kindly provided by
Dr Doo-Hyun Chung (Seoul National University, Seoul, Korea). The Rag 1 /
mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
The IFN-g-reporter-eYFP (GREAT) mice on a C57BL/6 background were kindly
provided by Dr Richard M. Locksley (University of California, San Francisco,
USA). The IL-2Rg /Rag2 / mice were purchased from Taconic
(Germantown, New York, USA) All mice were used at 6–10 weeks of age and were
bred and maintained in the speciﬁc pathogen-free vivarium of Seoul National
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University. All animal experiments were approved by the Institutional Animal Care
and Use Committee (IACUC) at Seoul National University.
Human samples. The human tumour tissue and normal tissue specimens from
patients with colorectal, melanoma and bladder cancer were cut into small pieces at
the Department of Surgery, Shinchon Severance Hospital, Yonsei University Col-
lege of Medicine.
Human peripheral blood was obtained from healthy volunteers, and informed
consent was granted from all donors. Peripheral blood mononuclear cells were
prepared by Ficoll-Hystopaque (Sigma-Aldrich, USA) density gradient
centrifugation. The collection of human samples and all human experiments were
approved by the ethical committee of Seoul National University and Shinchon
Severance Hospital, Yonsei University College of Medicine.
Reagents and antibodies. The antibodies for ﬂow cytometry and western blot
assays were purchased from Biolegend (San Diego, CA, USA), eBioscience (San
Diego, CA, USA), BD Bioscience (San Jose, CA, USA) and Cell Signaling Tech-
nology (Danvers, MA, USA). Antibody information can be found in
Supplementary Table 1. All microbeads (CD3e, CD11b, CD19, CD14, B220,
EpCam and Biotin) for lymphocyte depletion or selection were purchased from
Miltenyi Biotec (Bergish Galdbach, Germany). The antibodies for in vivo depletion
(Asialo GM-1, NK1.1 (PK136), CD4 (GK1.5), CD8 (2.43), IL-21R (4A9) and IFN-g
(XMG 1.2)) were prepared in the laboratory or purchased from Biolegend or
BioXcell. The recombinant mouse IL-2, mouse IL-21, human IL-2, human IL-21,
ULBP2 and human NKp46 antibodies were purchased from R&D Systems. Che-
mical inhibitors, including S31-201, Fludarabine, LY294002 and PD98059, were
purchased from Selleckchem (Houston, TX, USA).
Cell line generation and culture. The TC-1, CT26, MC38, K562 and HeLa cells
were purchased from ATCC. The cells were cultured in DMEM or IMEM (GIBCO)
supplemented with 10% FBS (GIBCO) and 1% penicillin-streptomycin. The opti-
mized sgRNA constructs, targeting H-2Kb (Exon 3: 50-AGCCGTCGTAGGCG-
TACTGCTGG)-30, H-2Db (Exon 3: 50-AGTCACAGCCAGACATCTGC TGG)-30 ,
mouse Beta 2 microglobulin (Exon 2: 50-TCACGCCACCCACCGGAGAATGG)-30
and human Beta 2 microglobulin (Exon 1: 50-GAGTAGCGCGAGCA-
CAGCTAAGG)-30 , and the Cas9 expression construct, pRGEN-Cas9-CMV, were
obtained from ToolGen (Seoul, Korea). The TC-1 H-2Kb and H-2Db, MC38 H-2Kb
and H-2Db, CT26 Beta 2 microglobulin and HeLa Beta 2 microglobulin knock out
cell lines were generated by transfection with the indicated sgRNA construct and
pRGEN-Cas9-CMV using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. MHC class I-deﬁcient cells were sorted by a T7E1 assay
with single cell selection or with a FACSARIA III (BD Bioscience). For primary cell
cultures, mouse primary cells were cultured in RPMI (GIBCO) medium supple-
mented with 10% FBS (GIBCO) and 1% penicillin-streptomycin (Lonza). Human
primary cells were cultured in X-VIVO15 medium (Lonza) that was supplemented
with 1% penicillin-streptomycin (Lonza). For NK cell culture, a low dose
(1B2 ngml 1) of rIL-2 was added to the culture medium for cell survival. All cell
lines were found to be negative for mycoplasma contamination.
Construction of recombinant adenoviruses. All adenoviral vectors were con-
structed by Cellid, Inc. (Seoul, Korea). To construct the adenoviral vector that
expressed the HPV antigen E6/E7 gene in the E1 region of adenovirus, we ﬁrst
constructed a pShuttle-CMV vector (Agilent Technologies, CA, USA) that
expressed the HPV antigen E6/E7 protein. The newly generated pShuttle-CMV-
E6E7 vector was co-transformed with the pAdeasy-1 adenovirus vector (Agilent
Technologies, CA, USA) in which a portion of the Ad type 5 ﬁbre was replaced by a
portion of the Ad type 35 ﬁbre (Adk35), yielding the plasmid pAdk35-E6E7. This
recombinant plasmid was transfected into human embryonic kidney 293 cells to
generate the Adk35-E6E7 adenovirus.
B/MoAdk35-E6E7/aGC and B/Mo/aGC preparation. Splenocytes were isolated
from C57BL/6 or BALB/c mice. The granulocytes and RBCs were removed by
Ficoll (Sigma-Aldrich) density gradient centrifugation. After the depletion of
CD3eþ and DX5þ cells from the cell population using anti-mouse CD3e and
anti-mouse DX5 microbeads, the CD11bþ cells and B220þ cells were puriﬁed
using anti-mouse CD11b and anti-mouse B220 microbeads (all from Miltenyi
Biotec). Isolated B cells and monocytes (1:1 ratio mixture) were transduced with
the indicated adenoviral vector in a 9-min, 2,800-r.p.m. centrifugation step at room
temperature, and the cells were subsequently incubated for an additional 18 h (for
the B/Mo/aGC preparation this step was skipped). aGC (KRN7000, Enzo Life
Science, Japan) was loaded into the prepared B cells and monocytes for NKT
activation based on our previous studies20–22,51.
Transplant tumour and therapeutic tumour models. Conventional subcutaneous
indicated tumours were generated by s.c. injection in the right ﬂank. Tumour
growth was measured using a metric calliper 2–3 times a week. In some experi-
ments, tumour cells were injected s.c. in the ﬂank after being resuspended in
Matrigel with reduced matrix growth factor (BD Bioscience). For the therapeutic
tumour model, 1 104–1 106 of the indicated tumour cells were subcutaneously
injected into the left ﬂanks of the mice on day 0. After the randomized and blinded
allocation of all tumour-bearing mice, the indicated vaccine or cytokine was
administered at various time points. For the TC-1 lung metastasis model, 1 105
cells were injected i.v. into the tail vein after resuspension in 100 ml phosphate-
buffered saline (PBS). Tumour formation was monitored using IVIS Spectrum
microCT and Living Image (ver. 4.2) software (PerkinElmer, Cambridge, UK). An
MMPSense 680 probe (PerkinElmer; 2 nmol per 150ml in PBS) was used to
facilitate tumour monitoring. For adoptive transfer into the IL-2Rg /Rag2 /
mice, tumour cells were subcutaneously injected into the left ﬂank of the mice, and
on the next day, the indicated cells were transferred by i.v. injection into the tail
vein. In addition, the transferred groups of No treatment, Tim-3 PD-1 NK cells
and IL-21-treated Tim-3þ PD-1þ eYFP NK cells were injected daily with rIL-21
(2 mg) via i.p. for 4 days. To deplete NK1.1þ , CD4þ , CD8þ cells, 300mg of GK1.5,
2.43, PK136 or control antibodies were injected i.p. twice weekly into the mice the
day before tumour implantation. To block IL-21R or IFN-g, anti-IFN-g (500 mg per
mouse) or anti-IL-21R (300 mg per mouse) or both were injected i.p. nine days after
tumour implantation, and two days later, the indicated cellular vaccine was injected
along with the neutralizing antibodies.
Antibody staining and ﬂow cytometry analysis. Dead cells were excluded by
staining with Fixable Viability Dye (eBioscience, CA, USA) following the manu-
facturer’s instruction. The cells were stained with the speciﬁed antibodies in 50 ml of
FACS buffer (PBSNþ 1% FBS). Intracellular staining for cytokines was performed
after surface staining with the Cytoﬁx/Cytoperm kit (BD Bioscience). For tran-
scription factor staining, the Foxp3/Transcription factor staining buffer set
(eBioscience) was used. In addition, for the intracellular staining of p-ERK, p-AKT,
p-FOXO1, pSTAT1 and pSTAT3, the cells were ﬁxed with IC ﬁxation buffer and
permeabilized with 1ml ice-cold 90% methanol on ice for at least 30min in the
dark after surface staining. The samples were acquired with a FACSCalibur or
FACSARIA III instrument (BD Bioscience), and the data were analysed with Flow
Jo software (Three Star).
Tumour-inﬁltrating lymphocyte preparation. Tumours were dissociated using
the gentleMACS Dissociator (Miltenyi Biotec). The dissociated tumour samples
were further digested in 10% FBS with RPMI medium containing 300 mgml 1
collagenase D (Roche), 20mgml 1 hyaluronidase (Sigma Aldrich) and 20 mgml 1
DNase I (Sigma Aldrich). After ﬁltering through a 40-mm nylon mesh, single cell
suspensions were counted and used for the experiments.
In vitro cytotoxicity assay. Effector CD8þ cells were prepared from vaccinated
mouse splenocytes and stimulated with the E641-50 [EVYDFARDL]/E749-57
[RAHYNIVTF] peptide mixture for 5 days. After the 5-day stimulation, CD8þ T
cells were isolated using anti-mouse CD8 microbeads (Miltenyi Biotec) and co-
cultured with 51Cr-labelled TC-1 tumour cells for 4 h. The CTL activity was cal-
culated by the release of 51Cr in the culture supernatants through the speciﬁc lysis
of TC-1 target cells, as measured by a Wallac 1480 Wizard automatic g-counter
(PerkinElmer). NK cells were prepared from vaccinated mouse splenocytes or
inﬁltrating lymphocytes from MHC class I-deﬁcient tumour-bearing mice or
human inﬁltrating NK cells from cancer patients by FACSARIA II or FACSARIA
III sorting. Next, various numbers of NK cells were co-cultured with 51Cr-labelled
TC-1 H-2Kb and H-2Db KO cells or K562 cells. The NK-cell cytotoxicity was
calculated by 51Cr release in the culture supernatants through the speciﬁc lysis of
TC-1 H-2Kb and H-2Db KO target cells or K562 cells, as measured by a Wallac
1480 Wizard automatic g-counter (PerkinElmer). To assay the cytokine release
from NK cells, 3 104B1 106 cells were stimulated in ﬂat-bottomed, high
protein-binding plates (Corning) that were coated with anti NK1.1, ULBP-2 Fc
protein or hNKp46 antibodies for 5 h in the presence of 1 mgml 1 GolgiPlug (BD)
before staining the cells for intracellular IFN-g, perforin or granzyme B. In some
experiments, CD107a was added during cell stimulation. When NK cells were co-
cultured with tumour cells, the tumour cells were irradiated (5,000 rads) using a
gamma irradiator (GC 3000 Elan) at the National Center for Inter-university
Research Facilities (NCIRF) at Seoul National University.
Immunoblot analysis. The cytoplasmic fractions of cells were prepared as follows:
cells were washed once with ice-cold PBS and collected by centrifugation at
3,000 r.p.m. for 5min. The cells were resuspended in 10mM HEPES, pH 7.9,
10mM KCl, 0.2mM EDTA, 1mM DTT, 0.25mM PMSF, and proteinase inhibitor
cocktail. After incubation on ice for 5min, NP-40 was added to a ﬁnal con-
centration of 0.25%. The mixtures were vortexed at high speed for 10 s. The
extracts were collected by centrifugation at 13,000 r.p.m. for 1min. The super-
natants were collected as cytoplasmic extracts. The uncropped scans of the western
blot were provided as Supplementary Fig. 17.
Immunohistochemistry. Tumour tissues were ﬁxed in 4% paraformaldehyde;
parafﬁn-embedded tissue sections (4mm) were deparafﬁnized, dehydrated and
treated with 3% hydrogen peroxide to block endogenous peroxidase. Slides were
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incubated with the primary antibody (Anti-MHC class 1 H-2 Db antibody, Abcam
Inc, MA, USA). Slides were then washed with PBS, incubated with HRP secondary
antibody and washed again in PBS; colour was developed using the AEC substrate.
The slides were counterstained with haematoxylin.
Enzyme-linked immunosorbent assay. The following cytokines were measured
in mouse serum using an ELISA kit according to the manufacturer’s instructions:
IL-21 (eBioscience), IFN-g, TNF-a and IL-4 (BD Bioscience, San Jose, CA, USA).
Statistics. Statistical comparisons were performed using the Prism 6.0 software
(GraphPad Software). P values were determined as follows:
 One-way ANOVA Kruskal–Wallis test with Dunn’s multiple comparisons:
Supplementary Fig. 14B, D and E. Two-way ANOVA with Bonferroni multiple
comparisons test: Figs 1a,b,2a–g and 5g–i,k, Supplementary Figs 1A–C,9B,14A and 16.
 Unpaired two-tailed Student’s t-test: Figs 3a–e and 4b–e, 5b,d,f and 6b,d,f,g,
7b–e, Supplementary Figs 6A,7C,11A,B,12B,13 and 15.
 A log-rank (Mantel–Cox) test (conservative): Figs 1c,2h–j.
Data availability. All data of this study are available within the article and its
Supplementary Information ﬁles or from the corresponding author on reasonable
request.
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